Browsing by Author "Ozkurt, Zubeyde Nur"

Now showing 1 - 4 of 4

Haploidentical Versus Matched Sibling Donor Hematopoietic Stem Cell Transplantation for Adult Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia: A Study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation
(2021) Nagler, Arnon; Labopin, Myriam; Pioltelli, Pietro; Arat, Mutlu; Yakoub-Agha, Ibrahim; Kulagin, Aleksandr D.; Angelucci, Emanuele; Ozdogu, Hakan; Risitano, Antonio; Ciceri, Fabio; Ozkurt, Zubeyde Nur; Sanz, Jaime; Brissot, Eolia; Peric, Zinaida; Giebel, Sebastian; Mohty, Mohamad
An interim analysis of the Turkish Myeloma Registry among patients who have received up to two lines of therapy
(2021) Sevindik, Omur Gokmen; Ozkurt, Zubeyde Nur; Boga, Can; Besisik, Sevgi Kalayoglu; Ipek, Yildiz; Geduk, Ayfer; Harmandali, Aybuke; Salihoglu, Ayse; Sahin, Handan Haydaroglu; Sonmez, Mehmet; Vural, Filiz; Akay, Olga Meltem; Yuksel, Meltem Kurt; Maral, Senem; Ekinci, Omer; Kirkizlar, Hakki Onur; Tekinalp, Atakan; Demir, Nazli; Merter, Mustafa; Saydam, Guray; Alacacioglu, Inci; Yegin, Zeynep Arzu; Kasar, Mutlu; Mastanzade, Metban; Ozsan, Guner Hayri
Investigation of JC Virus Positivity By Real-time Polymerase Chain Reaction in Patients with Hematopoietic Stem Cell Transplant
(2020) Colak, Meryem; Kocak, Aylin Altay; Kaynar, Lale Aydin; Ozkurt, Zubeyde Nur; Yegin, Zeynep Arzu; Bozdayi, Gulendam; 0000-0002-0451-0142; AAI-8012-2021
Introduction: In immunocompromised hosts, JC virus (JCV) can reactivate and cause a lytic infection of oligodendrocytes, resulting in progressive multifocal leukoencephalopathy (PML). Bone marrow is an important reservoir and possible site of neurotropic transformation for JCV. The aim of this retrospective study was to investigate the prevalance of JCV infection by real-time polymerase chain reaction (PCR) in patients sent from bone marrow transplant service to the laboratory in our hospital. Materials and Methods: A total of 153 clinical samples obtained from 62 patients with hematopoietic stem cell transplant between December 2013 and April 2018 were included into the study. Viral nucleic acids were extracted from the samples with QIAamp DSP Virus Kit in EZ1 Advanced (Qiagen, Germany) device. Isolated viral DNA was amplified with Real Star (R) JCV PCR Kit in Rotor-GeneQ (Altona, Germany) and JCV DNA was detected with qualitative method. Results: Sixty-two patients, 35 (56.5%) males and 27 (43.5%) females, between 18 years and 71 years of age were included into the study. Total JCV DNA positivity rate was found as 11.1% (17/153). Patients' diagnosis was respectively as follows: 45.2% acute myeloid leukemia, 19.4% acute lymphoblastic leukemia, 9.7% multiple myeloma. 6.4% myeloblastic sendrome, 6.4% non-Hodgkin lymphoma, 6.4% Hodgkin lymphoma, and 6.4% anemia. The distribution of JCV DNA positivity rates was found respectively as 40% acute myeloid leukemia, 30% multiple myeloma, 10% Hodgkin lymphoma, 10% acute lymphoblastic leukemia and 10% Non-hodgkin lymphoma. It was observed that 50% of JCV DNA positive patients died in the follow-up period after hematopoietic stem cell transplantation. Conclusion: It is not possible to diagnose JCV infections clinically because they are usually asymptomatic. However, up to 90% of those diagnosed with PML die within the first six months receiving a diagnosis. Detection and clinical surveillance JCV DNA by real-time PCR for hematopoietic stem cell transplantation patients is important for early diagnosis and treatment.
Long-term Results of Imatinib Discontinuation in Patients with Chronic-phase Chronic Myeloid Leukemia: A National Multicenter Prospective Study
(2023) Savas, Emine Merve; Yilmaz, Seda; Dikyar, Ayse Asena Baser; Ozkurt, Zubeyde Nur; Ocal, Ramazan; Can, Ferda; Pepeler, Sezgin; Kaynar, Lale Aydin; Gokcen, Sanem; Yildiz, Abdulkerim; Albayrak, Murat; Karakus, Sema; Ceneli, Ozcan; Yagci, Munci; 37877113
Objective: The discovery of imatinib was a milestone for chronic myeloid leukemia (CML). As the life expectancy of CML patients has approached that of the general population, research has shifted towards improving quality of life and economic considerations. After 2010, it was shown that some patients could maintain molecular response even after discontinuing imatinib. This national multicenter prospective cohort study aimed to observe the long-term consequences of discontinuing imatinib therapy in adult chronic-phase CML patients. Materials and Methods: We enrolled 41 CML patients from 4 different centers in this non-randomized single-arm trial. Molecular responses of all patients were re-evaluated using real-time polymerase chain reaction at a single center. The median follow-up time after imatinib discontinuation was 48 months (minimum-maximum: 6-81 months). Results: The rate of molecular relapse-free survival at 48 months was 33.2% (confidence interval: 48.2-18.2). Twenty-seven of 41 patients lost their major molecular response, treatment was started again, and deep molecular response was re-achieved with imatinib in all cases. There was no significant relationship between molecular relapse and clinical factors such as duration of treatment or molecular response status. Discontinuing imatinib resulted in savings of approximately 4,392,000 Turkish lira or 245,150 US dollars. Conclusion: Tyrosine kinase inhibitor discontinuation with close molecular monitoring is a safe option and provides important national economic benefits for chronic phase CML patients. This approach should be considered for all eligible patients. This is the first tyrosine kinase inhibitor discontinuation study from Turkiye.